Regenesance – Amsterdam Academic Ventures

Our portfolio

Regenesance

Regenesance focuses on antibody engineering to treat neurodegenerative diseases and immune-mediated disorders. The company licenses its technology to Complement Pharma, aiming to develop therapies for conditions like ALS and multiple sclerosis. The company leverages groundbreaking research to improve patient outcomes.

Industry: Immunology, Therapeutics

Want to get in contact about Regenesance?

We’re happy to connect. Reach out to our investment manager working with the team to learn more or explore potential opportunities.

Marc Roelofs

Life Science & Health

Our portfolio

Check out similar ventures

Pioneering cancer vaccines, DCPrime leverages its DCOne® dendritic cell technology to develop innovative immunotherapies.

AI-powered portable EEG for real-time stroke severity detection.

Providing advanced defect detection for carbon composites in aerospace and wind energy.

Using AI to restructure audio data, such as podcasts and webinars.

Pioneering cancer vaccines, DCPrime leverages its DCOne® dendritic cell technology to develop innovative immunotherapies.

AI-powered portable EEG for real-time stroke severity detection.

Providing advanced defect detection for carbon composites in aerospace and wind energy.

Using AI to restructure audio data, such as podcasts and webinars.

Our portfolio

Want to get in contact about Regenesance?

Marc Roelofs

Our portfolio

Holdings of our founding institutes

Contact